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Activation of platelet-activating factor receptor
exacerbates renal inflammation and promotes fibrosis
Matheus Correa-Costa1, Vinicius Andrade-Oliveira1, Tarcio T Braga1, Angela Castoldi1, Cristhiane F Aguiar1,
Clarice ST Origassa2, Andrea CD Rodas1, Meire I Hiyane1, Denise MAC Malheiros3, Francisco JO Rios1,4,
Sonia Jancar1 and Niels OS Caˆmara1,2
Platelet-activating factor (PAF) is a lipid mediator with important pro-inflammatory effects, being synthesized by several
cell types including kidney cells. Although there is evidence of its involvement in acute renal dysfunction, its role in
progressive kidney injury is not completely known. In the present study, we investigated the role of PAF receptor (PAFR)
in an experimental model of chronic renal disease. Wild-type (WT) and PAFR knockout (KO) mice underwent unilateral
ureter obstruction (UUO), and at kill time, urine and kidney tissue was collected. PAFR KO animals compared with WT
mice present: (a) less renal dysfunction, evaluated by urine protein/creatinine ratio; (b) less fibrosis evaluated by collagen
deposition, type I collagen, Lysyl Oxidase-1 (LOX-1) and transforming growth factor b (TGF-b) gene expression, and higher
expression of bone morphogenetic protein 7 (BMP-7) (3.3-fold lower TGF-b/BMP-7 ratio); (c) downregulation of extra-
cellular matrix (ECM) and adhesion molecule-related machinery genes; and (d) lower levels of pro-inflammatory cytokines.
These indicate that PAFR engagement by PAF or PAF-like molecules generated during UUO potentiates renal dysfunction
and fibrosis and might promote epithelial-to-mesenchymal transition (EMT). Also, early blockade of PAFR after UUO leads
to a protective effect, with less fibrosis deposition. In conclusion, PAFR signaling contributes to a pro-inflammatory
environment in the model of obstructive nephropathy, favoring the fibrotic process, which lately will generate renal
dysfunction and progressive organ failure.
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Renal fibrosis is considered as the hallmark of chronic kidney
disease (CKD), and epidemiological studies have shown that
the prevalence of patients with progressive renal failure is
increasing worldwide. As a consequence, CKD has become
not only a global health issue, but also an economic problem,
affecting individuals, families and societies.1–5 Under normal
conditions, the renal interstitial space is formed of few cells
(fibroblasts and resident immune cells) and peritubular
capillaries. These structures are incorporated in the extracel-
lular matrix (ECM), and the production of its components is
well controlled to keep tissue homeostasis. In a fibrotic
situation, the interstitial space is filled with numerous cells
(fibroblasts, myofibroblasts, infiltrating immune cells and
atrophic tubular cells), there is rarefaction of peritubular
capillaries and concomitant excessive production of ECM
proteins.6
A suggested mechanism that contributes to the fibrotic
process is the epithelial-to-mesenchymal transition (EMT),
in which epithelial cells undergo differentiation and start to
express mesenchymal markers, changing their phenotype
and producing ECM compounds.7 In this sense, fibroblast-
specific protein 1 (FSP-1), a filament-associated molecule,
present in fibroblast, but not in epithelium, mesangial cells or
embryonic endoderm, can be used as a marker of EMT.8 Such
process has been described in a variety of different tissues,
such as kidney, liver, lung, colon and heart, although the
molecular mechanisms involved are not yet completely
understood.3,9–13
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Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sngly-
cero-3-phosphocholine) is a lipid mediator of inflammation.
During kidney inflammation, PAF is synthesized by inflam-
matory cells that infiltrate the tissue and/or by mesangial
cells.14 PAF acts on a G-protein coupled receptor (PAFR)
expressed in monocytes/macrophages, polymorphonuclear
leukocytes, platelets, endothelial cells and many other cell
types.15 PAF or oxidized molecules with PAF-like activity
generated during stress situations such as hypoxia can engage
the PAFR, which activates intracellular signaling pathways
that lead to transcription of pro-inflammatory genes.16
Although PAF is involved in acute renal dysfunction17 its
role in renal fibrosis and in EMT is not completely known.
One of the most used experimental model of CKD is the
unilateral ureter obstruction (UUO) model. Such procedure
leads to cellular infiltration (mainly macrophages), disequi-
librium between apoptosis and proliferation of tubular cells,
as well as fibroblast activation and proliferation, with
consequent ECM production and fibrosis deposition. On
the basis of this, the aim of this study was to investigate the
involvement of PAFR in CKD. To this purpose, we employed
the UUO model and compared mice lacking PAF receptor
(PAFR knockout (KO)) with wild-type (WT) animals.
MATERIALS AND METHODS
Ethics Statement
The animals used in this work were housed in individual
standard cages and were kept on a 12-h light/dark cycle in a
temperature-controlled room at 21–23 1C, with free access to
water and food. All procedures were approved by the internal
ethical committee of the University of Sa˜o Paulo (Documents
118/2009 and 122/2012).
Animals and Treatment
Balb/c PAFR KO mice were kindly provided by Professor
Takao Shimizu (University of Tokyo)18 and were bred and
maintained under SPF conditions at Institute of Biomedical
Sciences at the University of Sa˜o Paulo. Balb/c (WT) mice
were obtained from our Isogenic Breeding Unit (Immuno-
logy Department, Biomedical Science Institute, University of
Sao Paulo). Mice were divided into three groups: control
(n¼ 5)—mice that did not suffer any surgical procedure; WT
(n¼ 5)—WT Balb/c mice that underwent UUO surgery and
PAFR KO (n¼ 5)—PAFR gene genetic engineered mice that
underwent UUO surgery. In a set of experiments, the animals
were treated with the PAFR antagonist WEB2170 (kindly
supplied by Boehringer Ingelheim, Pharma KG, Biberach,
Germany), at the dose of 5mg/kg during the first 3 days of
surgery (described below).
Experimental Model of UUO
Mice were anesthetized with Ketamine–Xylazine (Agribrands
do Brazil, Sa˜o Paulo, Brazil) unless otherwise stated. On day
0, UUO was performed by complete ligation of the left ureter
with 4–0 silk at two points, and an incision made between the
points of ligation. Animals were placed in single cages and
warmed by indirect light until completely recovered from
anesthesia. After recovery, animals were kept under normal
housing condition until killing.
Renal Function Evaluation
Urinary protein/creatinine ratio was measured in samples
collected from the obstructed pelvis at 7 days post surgery. All
samples were analyzed by colorimetric assays using commer-
cially purchased kits for creatinine and protein measurements
(Labtest, Lagoa Santa, Brazil). The ratio was normalized by
dividing ratio at day 7 by the ratio before surgery in each
group of animals. To estimate the urinary albumin con-
centration, 10 ml of urine was diluted in sample buffer v/v,
run on a 10% SDS-polyacrylamide electrophoresis gel and
then stained with Commassie blue, as described previously.19
Histomorphometric Analysis
Formaldehyde-fixed paraffin sections of the kidneys were
stained with Picrosirius for evaluation of fibrosis deposition.
Renal histomorphometric analyses were made by two ‘blin-
ded’ renal histologists. Picrosirius-stained sections were
analyzed by an Olympus BX50 microscope with an Olympus
camera attached (USA). Manual shots were taken of the
cortex, magnified  40, and observed under polarized light.
Photos of at least five different fields in each slide were taken,
and structures such as glomeruli, subcapsular cortex, large
vessels and medulla were excluded. The pictures were digi-
talized (HP Scanjet 2400) and then the interstitial volume of
collagen in the cortex compared with the overall cortex area
was quantified by morphometry. For the morphometric
analysis, the Image Processing and Analysis in Java, Image J
software was used. The result of the analysis is represented by
the percentage, and refers to the proportion of the interstitial
volume of collagen in the cortex to the total cortical inter-
stitial volume, and then the arithmetic mean of the analyzed
fields was calculated for each slide.
Immunohistochemistry
Localization of FSP-1 (diluted 1:500; DAKO, Ely, UK) and
PAFR (diluted 1:200; Cayman Chemical, Denver, USA) was
assessed in paraffin-embedded tissue sections. Human slides
were used for PAFR expression. The samples were obtained
from the healthy portion of the kidney of a nephrectomized
patient with renal tumor, and from a biopsy of a patient’s
kidney with diabetic nephropathy. The slides were depar-
affinized, rehydrated and subjected to a Tris-EDTA (pH 9)
antigen retrieval solution at 95 1C. The endogenous perox-
idase activity was blocked with 3% hydrogen peroxide, and
sections were additionally blocked with Protein Block Solu-
tion (DAKO). Slides were incubated with a primary antibody
or isotype non-specific IgG as a negative control reagent,
followed by incubation with the labeled polymer Envision
(DAKO), using two sequential 30-min incubations at room
temperature. Staining was completed by a 1- to 3-min
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incubation with 3,39-diaminobenzidine (DAB)þ substrate
chromogen, which stains the specific antigen brown. Hema-
toxylin counterstaining was also done.
Gene Profiles
Kidney samples were snap-frozen in liquid nitrogen. Total
RNA was isolated from kidney tissue using the TRIzol
Reagent (Invitrogen, Carlsbad, USA) and protocol according
to Invitrogen. RNA concentrations were determined by
spectrophotometer readings at absorbance 260 nm. First-
strand cDNAs were synthesized using the MML-V reverse
transcriptase (Promega, Madison, USA). RT-PCR was per-
formed using the Taqmanor Syber Green real-time PCR assay
(Applied Biosystem, USA) for the following molecules:
hypoxanthine-guanine phosphoribosyl transferase (HPRT)
(Mm00446968_m1), type I collagen (Mm00801666_g1),
Lysyl Oxidase-1 (LOX-1) (Mm01145738_m1), TGF-b
(Mm01178820_m1), bone morphogenetic protein 7 (BMP-7)
(Mm00432102_m1), PAFR (Mm00731507_s1), PAF-acetyl-
hydrolase (PAF-AH) (F-GTCTCTGCTTCAGAGGATGC and
R-ACATTGTGATCGTGACCGTG) and Lysophosphatidylc-
holine acyltransferase (PAF-AT) (F-CCAGGTGGCATT-
TAAGCTCT and R-TCTTGGCATATTCTGGGTGC). Cycling
conditions were as follows: 10min at 95 1C followed by 45
cycles at 20 s each at 95 1C, 20 s at 58 1C and 20 s at 72 1C.
Analysis used Sequence Detection Software 1.9 (SDS). mRNA
expression was normalized to HPRT expression. Also, Mouse
Extracellular Matrix and Adhesion Molecules PCR array was
performed (PAMM013—from Qiagen, The Netherlands),
comparing control, WT and PAFR KO groups.
ELISA for TGF-b
Total TGF-b1 protein was measured by ELISA (TGF-b1
Emaxs, Promega). Kidney cells were lysed in RIPA buffer
and protein levels quantified by DC Protein Assay (Bio-Rad,
Hercules, USA). After overnight coating of a 96-well plate
with a primary antibody, TGF-b1 was detected in cell lysates
using a secondary antibody. The system uses horseradish
peroxidase-conjugated secondary antibody and a single-
component TMB substrate for the final chromogenic detection
of bound TGF-b1. Using this assay, biologically active TGF-
b1 can be detected in the range of 15.6–1000 pg/ml. Results
are expressed as ng/mg of TGF-b protein.
Bioplex
Kidney cells were lysed in RIPA buffer with protease inhi-
bitor. A Bio-Plex mouse Plex cytokine assay kit (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) was used to test
samples for the presence of several cytokines. The assay was
read on the Bio-Plex suspension array system, and the data
were analyzed using Bio-Plex Manager software version 4.0.
Standard curves ranged from 32 000 to 1.95 pg/ml.
Assessment of Apoptosis
To detect apoptotic cells, the In situ Cell Death Detection Kit
TMR red (Roche Diagnostics GmbH, Mannheim, Germany)
was used (TUNEL Technology) in paraffin-fixed tissues.
Statistics
The data were described as mean±s.e.m. Differences among
groups were compared using ANOVA (with Tukey post-test)
and Student’s t-test. Significant differences were regarded as
Po0.05. All statistical analyses were performed with the aid
of GraphPad PRISMs.
RESULTS
PAFR Is Expressed in Renal Tissue of Mice and Humans
with CKD
First, we evaluated the time course of PAFR expression after
induction of the UUO surgery. We observed that there is an
early upregulation of this receptor within 1 day, and that its
expression keeps elevated until later time points—with a
peak on day 5 post surgery (Figure 1a). Also, to verify what
cell type would be responsible for such expression, we per-
formed IHC for PAFR in a time-course experiment. As
observed in Figure 1b, at the early moments after UUO
(1 and 3 days) there is a stronger staining for PAFR in the
infiltrating cells. But, at later points (5 and 7 days) the renal
cells also express higher levels of PAFR. As a control, we also
performed the same staining in PAFR KO mice, and we did
not see any PAFR expression in these groups.
To reinforce that PAFR is expressed during the development
of CKD, we obtained human kidney slides and performed
IHC for that receptor. As observed in Figure 1c, the healthy
portion of the kidney from a nephrectomized patient with
renal tumor shows no staining for PAFR. On the other
hand, a biopsy sample of the kidney from an advanced
diabetic patient, with diabetic nephropathy (one of the most
common cause of CKD), shows a clear and strong staining
for PAFR in the cortical tubular area. Together, these
data indicate that PAFR is present during progressive renal
disease.
UUO-Induced Renal Dysfunction Is Reduced in PAFR-
Deficient Mice
Once PAFR seems to be involved in the obstructive ne-
phropathy, we decided to evaluate whether the absence of
PAFR (PAFR KO mice) would attenuate renal dysfunction
following progressive kidney disease. For that, we submitted
PAFR KO mice to UUO surgery, killing them after 7 days. As
PAF results from the balance of its production and
degradation, we decided to check the gene expression of two
PAF-related key enzymes: the PAF-AT, responsible for its
production, and PAF-AH, a mediator of its degradation. As
the balance of these two molecules can indirectly presume
PAF levels, we made a ratio regarding production/degrada-
tion. As observed in Figure 2a, WT mice submitted to UUO
show higher levels of the PAF-AT/PAF-HA ratio than control
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Figure 1 PAFR is present during progressive kidney disease. (a) PAFR kinectics after UUO (*Po0.05 vs Control and **Po0.01 vs Control). In (b),
immunohistochemistry for PAFR was assessed in control mice and in WT animals at different time points after UUO. Also, the same staining was
performed in PAFR KO animals 7 days after UUO. The balck arrows show PAFR-positive infiltrating cells and red arrows show PAFR-positive staining in
renal cells. (c) Human slides were used for PAFR expression. The samples were obtained from the healthy portion of the kidney of a nephrectomized
patient with renal tumor, and from a biopsy of a patient’s kidney with diabetic nephropathy.
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or PAFR KO animals. Also, PAFR KO mice, compared with
WT animals, have less urinary protein excretion (Figure 2b),
and, moreover, decreased levels of urinary albumin, a marker
of kidney impairment (Figure 2c). Also, PAFR KO animals
showed decreased levels of urinary NGAL, a more sensitive
biomarker of kidney injury (Figure 2d). These data indicate
that PAFR, engaged by endogenous PAF or PAF-like mole-
cules produced during UUO, contributes to the development
of renal dysfunction.
Lack of PAFR Decreases Collagen Deposition
Next, we aimed to investigate whether the protection
observed in the renal function analysis in the PAFR KO mice
was a consequence of less collagen deposition in these ani-
mals. As observed in Figure 3, WT mice presented increased
collagen deposition after ureter obstruction, indicated by
Picrosirius staining. On the other hand, PAFR KO mice
showed less staining for collagen. We also evaluated the
protein expression of FSP-1—a marker of EMT—and once
more, in the PAFR KO group there is a marked reduction in
this parameter (Figure 3). We were able to quantify both
collagen deposition and FSP-1 staining, and we observed that
WT animals had significantly higher levels of these fibrotic
markers than control and PAFR KO (Figures 2e and f).
Moreover, PAFR KO mice presented significantly lower levels
of type I collagen mRNA when compared with WT litter-
mates (Figure 2g). In addition, we also observed that gene
expression of LOX-1, an important enzyme for collagen
production,20 is significantly reduced in KO animals
(Figure 2h). Taken together, these results indicate that the
deficiency of PAFR correlates with less fibrosis in kidneys
submitted to UUO.
UUO-Induced Pro-Fibrotic Signaling Is Reduced in PAFR-
Deficient Mice
The next step was to evaluate the role of PAFR in the
molecular mechanisms involved in fibrosis development. For
that, we quantified the levels of two known molecules
implicated in fibrotic processes, TGF-b and BMP-7.21 TGF-b
was overexpressed in WT mice in both transcriptional and
protein levels (active form), whereas in PAFR KO animals
such values were similar to control (Figures 4a and d). When
we analyzed BMP-7 expression, the opposite effect was
observed, with a significant upregulation in PAFR KO animals
(Figure 4b). As fibrosis results from an imbalance between
pro- and anti-fibrotic stimuli, we did a ratio between TGF-b/
BMP-7 expressions and found a striking difference between
WT and PAFR KO groups, favoring an anti-fibrotic state in
PAFR KO mice (Figure 4c).
To make sure that an overall pro-fibrotic signaling is
attenuated in PAFR KO animals, we performed a PCR array
for ECM and adhesion molecules. As observed in Figure 5a,
Figure 2 PAFR is important for fibrosis development during obstructive nephropathy. (a) Ratio between the mRNA levels of PAF-AT and PAF-AH in
control WT and PAFR KO groups. Renal function in WT and PAFR KO animals was assessed for (b) proteinuria and (c) albumin excretion. (d) Levels of
urinary NGAL, 7 days after UUO in WT and PAFR KO animals. Quantification of fibrosis deposition by Picrosirius staining is shown in (e) (*Po0.05 vs
Control and PAFR KO). In (f), quantification of FSP-1 staining (*Po0.05 vs Control and **Po0.01 vs Control and PAFR KO). (g) Gene expression of type I
collagen from WT and PAFR KO mice. (h) mRNA transcripts quantification of LOX-1 from the same animals stated before (*Po0.05 vs WT).
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the heat map of gene expression is quite similar between
control and PAFR KO mice, but striking different from WT
animals. Furthermore, when we compare UUO-submitted WT
or PAFR KO groups vs control group, we can observe that the
number of upregulated genes in the first group is much more
pronounced than in the PAFR KO one, suggesting once again
that the absence of PAFR promotes a global gene profile more
similar to the control group (Figures 5b and c). More inter-
estingly, when we compare WT and PAFR KO animals we can
see that ECM and adhesion molecules machinery genes are
greatly overexpressed in the first group (Figure 5d). The list of
downregulated and upregulated genes in each condition can be
checked in Supplementary Information, in the Supplementary
Tables 1, 2 and 3. All these data suggest that PAFR engagement
is important for a proper fibrogenic signaling.
PAFR KO Mice Have Less Prominent Inflammatory
Response
As PAF has been widely linked to inflammation and since this
process can accelerate fibrosis,22 we decided to evaluate the
inflammatory profile in kidney tissue homogenates after
7 days of UUO induction. Initially, we observed that the renal
tissue of WT animals showed an increase in the chemo-
attractant molecules KC and monocyte chemotactic protein-
1 (MCP-1), a fact that was noted in a significantly less extent
in PAFR KO mice (Figures 6a and b). Also, when we looked
for CD68 expression—a marker of macrophage population—
in kidney tissue, we observed that such molecule was more
than three-fold higher in WTmice, compared with PAFR KO
(Figure 6c).
The adaptive immune response can be activated as a
consequence of the inflammatory process. So, we decided to
take a look at some lymphocyte-related molecules. We observed
that PAFR KO mice have significantly less protein expression
for the lymphoproliferative molecule interleukin 2 (IL-2),
as well as a tendency to switch to a Th1 pattern, favoring an
anti-fibrotic signaling (Figures 6d–f). Still, we were able to
verify that the established pro-inflammatory molecules TNF-
a, IL-1b and IL-6 were significantly downregulated in PAFR
KO mice, when compared with WT animals (Figures 7a–c).
In counterpart, we noticed that the expression of the immuno-
suppressive molecule IL-10 was significantly increased in the
Figure 3 PAFR KO animals submited to UUO show less histologic changes than WT counterparts. Representative images of Picrosirius staining, under
normal and polarized light, and FSP-1 protein expression from control mice and WT and PAFR KO mice submitted to UUO.
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PAFR deleted gene group (Figure 7d). As a result, the
reduction in the inflammatory process led to less apoptosis in
the renal tissue of PAFR KO animals submitted to obstructive
nephropathy (Figure 7e). Together, these results show that
engagement of PAFR by PAF or PAF-like molecules produced
during UUO induces a pro-inflammatory profile with con-
sequent more cell death, which will later favor a pro-fibrotic
environment.
Early Pharmacological Blockade of PAFR Reduces Renal
Fibrosis
To go further regarding the link inflammation–fibrosis, we
decided to block PAFR during the onset of the disease. For
that, we treated WTmice with the PAFR antagonist WEB2170
at the first 3 days after UUO. As observed in Figure 8, the
treatment led to a decreased loss of urinary protein, lower
levels of urinary NGAL, despite less fibrosis deposition and
reduced expression of pro-fibrotic markers TGF-b and type I
collagen (Figure 8). These results confirm that early modula-
tion of the inflammatory process can attenuate the fibrotic
status of chronic diseases.
DISCUSSION
Renal fibrosis has become a global threat for public health,
once the number of patients with this problem is increasing
all over the world. The presence of a fibrotic kidney, and
consequently the establishment of CKD lead to a worst
prognosis with reduction in the quality of life and con-
sumption of huge amounts of money for treatment and/or
renal replacement therapies. Although there is an important
advance on the knowledge of the molecular pathways
involved in this fibrotic process, there is still a long road to
achieve, and the search for new therapeutic targets is of
extreme importance. Here, we provide evidence that PAFR
activation is involved in renal fibrosis, through a mechanism
that is, at least in part, due to EMT.
In this work, we showed that PAFR is upregulated early
after UUO induction and that its expression was kept ele-
vated until late time points, suggesting the importance of
such receptor during CKD. This corroborates other studies
that showed an increase of PAFR in the onset of different
diseases, like systemic infection, necrotizing enterocolitis,
graft-vs-host disease and peripheral nerve injury.23–26
As expected, initially, the infiltrating immune cells must be
responsible for PAFR expression upregulation, and at later
time points the renal cells are also responsible for the
maintenance of higher PAFR expression. PAF and a wide
range of oxidatively modified phospholipids are recognized
by PAFR that is constitutively expressed by cells participating
in innate immunity. Pathologic inflammatory responses
can be triggered if mechanisms that generate PAF or other
ligands recognized by the PAF receptor are dysregulated or
impaired.27
In a previous study, we found that oxidized lipids induce
the formation of a complex comprising PAFR and the scavenger
receptor CD36 within lipid raft platforms in macrophages
and this is required for gene expression and production of
TGF-b, Arg-1 and mannose receptors. Thus, activate mac-
rophage toward an alternative M2 phenotype,28,29 which are
related to the collagen production and fibrosis. These mecha-
nisms may be applied to the CKD, since oxidized lipids
are formed in during its pathogenesis.30 Besides, another
pathway that is downstream PAFR activation and that is
involved with TGF-b production is the MAPK ERK.31,32
Future studies linking these molecules should better elucidate
this issue.
Moreover, renal dysfunction has already been linked to an
increase in PAF levels. Mariano et al33 showed that patients
with sepsis-associated acute renal failure presented an
increase in serum and urinary PAF levels. Also, this increase
was associated with higher levels of the inflammatory
cytokines TNF, IL-1, IL-6 and IL-8.
As proteinuria is considered as a good marker of pro-
gressive renal dysfunction,34 we measured this parameter, as
well as albumin excretion, to compare WT and PAFR KO
animals. The reduction of protein excretion in PAFR KO
group indicates that endogenous PAF contributes to renal
Figure 4 Pro-fibrotic signaling is downregulated in PAFR KO animals.
Gene expression of TGF-b and BMP-7 is shown in (a and b), respectively
(*Po0.05 vs WT). In (c), it is shown the ratio TGF-b/BMP-7 (*Po0.05 vs
WT). (d) Indicates the protein expression of TGF-b in renal tissue of
control animals and WT and PAFR KO mice submitted to UUO (*Po0.05
vs control and PAFR KO groups).
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dysfunction. This is in accordance with previous studies that
showed, in isolated perfused rat kidney, that the addition of
PAF induced proteinuria, at similar levels to that induced by
angiotensin II.35 In addition, Torras et al36 showed that long-
term pharmacological blockade of PAFR protects from
progressive renal injury. On the other hand, another work
did not observe any difference concerning albuminuria levels
between animals treated or not with PAFR antagonist in the
ablation model of CKD.37 However, they used the 5/6
nephrectomy model, whereas we used the UUO model which
can explain the different results. The progression of renal disease
is complex and multifactorial, and an effect on the filtration
barrier could not be excluded to explain the proteinuria
reduction in PAFR KO animals.38 But, we believe that fibrosis
progression is also an important mediator of the urinary
protein loose. Moreover, renal fibrosis also has an effect on
the filtration barrier, facilitating the loss of protein within the
glomerular filtrate. There is evidence of PAF involvement in
fibrosis in different organs, like liver and lung.39,40 In our
study, the attenuated renal dysfunction observed in PAFR KO
mice correlated with lower levels of fibrosis. This is in
accordance with results from Doi et al,41 using the acid folic
model of renal injury. In addition, a classic study showed that
stimulation of PAFR promoted overexpression of ECM
proteins in renal tubule-interstitial cells.42
Recently, we have shown that inflammation is a pivotal
mediator of renal fibrosis, and that its modulation could
bring beneficial effects.19,43,44 In this current study, we were
able to confirm that PAFR is important for the inflammatory
process, not only contributing to chemotaxis, but also
activating innate and adaptive immune responses. PAF and
its receptor have been widely linked to inflammation,27,45–48
and is interesting to highlight that not only immune cells,
but also a great variety of cell types, from different organs,
show an increase in inflammatory signaling as a response to
PAF, for example, activating NF-kB, promoting superoxide
Figure 5 PAFR engagement increases ECM and adhesion molecules gene machinery. (a) Heat map comparing Control, WT and PAFR KO groups. Red
and green colors represent upregulated and downregulated genes, respectively. The color intensity indicates the extent of gene expression. (b) Dot
plot representation of upregulated (red dots) and downregulated (green dots) genes comparing UUO-submitted WT animals (group 1) vs control mice.
(c) Dot plot representation of upregulated (red dots) and downregulated (green dots) genes comparing UUO-submitted PAFR KO animals (group 2) vs
control mice. (d) Volcano graphic representation of upregulated and downregulated genes—red and green dots, respectively—comparing WT (group 1)
and PAFR KO mice (group 2) submitted to UUO.
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Figure 6 Lack of PAFR decreases immune infiltrating cells signaling. Protein expression of (a) KC and (b) MCP-1 was measured in kidney lysates from
control and WT and PAFR KO animals submitted to UUO (*Po0.05 vs control and PAFR KO groups). (c) Gene expression of CD68, a macrophage
marker, evaluated in renal tissue (*Po0.05 vs WT). Kidney protein expression of the lymphocyte-related molecules IL-2, IL-4 and IL-12 is shown in
(d–f) (*Po0.05 vs control and PAFR KO).
Figure 7 UUO-induced inflammation is reduced in PAFR KO animals. Protein levels of the pro-inflammatory molecules TNF-a (a), IL-1b (b) and IL-6 (c)
were measured in renal tissue (*Po0.05 vs control and PAFR KO mice). The immune regulatory molecule IL-10 also evaluated in kidney lysates
(d—*Po0.05 vs control and WT groups) was evaluated in renal tissue. Also, apoptosis was assessed and a representative image is shown in (e).
PAFR and renal fibrosis
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production, vasodilation and enhancement of cell migra-
tion.49 In addition, Venkatesha et al50 demonstrated that
PAF-induced CCL2 (also known as MCP-1) gene expression
requires NF-kB activation and Ca2þ /calcineurin signaling
pathways, showing a loop of amplification of the inflam-
matory process. Such information reinforces our MCP-1
data, suggesting that lack of PAFR decreases the production
of this chemokine. There is also evidence that engagement of
PAFR in macrophages induces regulatory phenotype.51 These
cells, also called M2 macrophages, have an important role in
tissue remodeling and repair but excessive activity of these
macrophages can induce fibrosis52
One more feature that we could observe during the
experiments was the reduced presence of apoptotic cells in
PAFR KO mice. Apoptosis is one of the hallmarks in UUO
model,53 which was also noticed in our WT group data.
Furthermore, PAFR signaling per se have been associated with
apoptosis.45,54,55 On the other hand, Ryan et al56 showed
that, in a model of neuronal toxicity, PAF could induce
apoptosis independent of its receptor.
Figure 8 Early blockade of PAFR attenuates renal progressive disease. (a) Proteinuria levels were evaluated in animals submitted to UUO and that were
treated or not with WEB2170. (b) Levels of urinary NGAL, 7 days after UUO in mice that were treated or not with WEB2170. In (c), we can see
representative images of the indicated groups after Picrosirius staining and polarized light evaluation. The quantification of fibrosis deposition can be
seen in (d) (*Po0.05 vs Control and **Po0.01 vs Control and UUOþWEB). The gene expression of type I collagen and TGF-b can be observed in
(e and f), respectively. *Po0.05 vs UUO.
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Finally, our results suggest that PAFR signaling must be
involved in EMT, as KO mice showed less gene and protein
expression for mesenchymal markers, maintaining an epi-
thelial phenotype. So far, no other publication has linked
PAFR to renal EMT, although some papers have shown that
PAF and/or PAFR have a role in the production of ECM
molecules.41,42 Some consolidated data indicate that the
balance of TGF-b/BMP-7 dictates the fibrotic state of an
organ, where the more production of the first molecule may
direct to a pro-fibrotic signaling. In counterpart, favoring
the BMP-7 production may generate a cytoprotective
state.10,21,57–64 This may provide another explanation for
the protection observed in PAFR KO mice, since in this group
there was a striking reduction in TGF-b/BMP-7 ratio,
compared with WT.
In conclusion, we postulate that PAF or PAF-like molecules
generated during UUO could engage PAFR and contribute to
renal fibrosis through induction of a pro-inflammatory
microenvironment. Also, we reinforce the involvement of
EMT in the development of CKD.
Supplementary Information accompanies the paper on the Laboratory
Investigation website (http://www.laboratoryinvestigation.org)
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